DMEI chooses ifa EMR v6 as future Electronic Medical Record system

ifa united i-tech, a U.S. subsidiary of ifa Systems AG, the global leader for IT solutions in ophthalmology, announced that the Dean McGee Eye Institute (DMEI) selected ifa EMR v6 as its future Electronic Medical Record (EMR) system.

"Health IT will play an important role in the future practice of ophthalmology," said Gregory Skuta, M.D., DMEI President and CEO. "We are dedicated to providing the highest level of patient care using the latest technology platforms. This decision, spanning two years, was based on a broad market analysis followed by a comprehensive evaluation of the leading EMR vendors. The entire DMEI team of clinicians, technicians, IT specialists and other future users were actively involved in the selection process."

"The Board and the entire team at ifa united i-tech are honored by the decision of the Dean McGee Eye Institute to choose ifa systems as its EMR application," said Rainer Waedlich, Chairman of ifa Systems, AG. "We are committed to the project and will establish, together with the DMEI team, a 'Center of Excellence' for Health IT in Ophthalmology."

Source:

ifa united i-tech

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exonate plans 'CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease